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-~  Clinical of Integrilin in Unstable Angina is Efficacy 
Accompanied by a Modest Increase in Hemorrhagic 
Risk: The PURSUIT Tdal 
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8.D. Weathedy. N.S. Kleiman. E.J. Topoi. For the PURSUIT Investigators. 
Cleveland Clinic Foundation. Cleveland. OH and Duke Clinical Research 
Institute. Durham, NC, USA 
Background: Integrilin" (Eptifibatide). a cyclic KGD pept~de inhibitor of the 
ptatelet GP lib/Ilia receptor, was evaluated in the randomized, double-blind. 
placebo-contrelled PURSUIT trial among 10,948 pts with unstable angina, 
Eptifibatide treatment (180 pg/kg bolus, 2.0 pg/kg/min infusion) for up to 
72-96 hre was assOCiated with an absolute 1.5°,'o reduction in the incidence 
of death or MI within 30 days (15.7 vs 14.2%, p = 0.0424). 
Methods: Bleeding complications during the hospitalization penod were 
defined as severe (intracraniat or causing hemodynamic v'ompromise), rood- 
erate (requiring transfusion), or mild (all other). 
Resuffs/Conclusions: Moderate or severe bleeding (most often at s~tes 
of vascular access) was increased with eptifibatide, particularly in pts who 
did not require bypass surgery. Thus, reduction in ischemic events with 
PlaCebO Eptifibatide 
Moderate or Severe Breed 9.9";, 128%" 
Moderate or Severe Bleed w/o CABG 2.0% 52% 
RBC or Whole Blood Transfusion 9.3% 11.8% 
Transfusion w/o CASG 1.8% 44¢'" 
Intracranial Bteed 0.09% 0.11% 
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Efficacy of  Abc ix imab in Patients With Unstable 
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For the CAPTURE InveStigators; Umversrty Hospdal Eppendort, Hamburg, 
Germany, ' Erasmus Unwermty Rotterdam. The Net,~erlancls 
Background: In patmnts (pts) wffh acute corenaw syndromes mc'roemboliza- 
t~on from ruptured atheroseterotic plaques may cause minor myocardial infury 
detectable by c=rcuta~ng troponms. This was shown to be assocmted with an 
adverse short and long term outcome. The CAPTURE teal demonslrated that 
platelet inhibition with abetximab reduces risk for myocardial infarction (AMI) 
at~J death in pts w,h refractory unstable angina p,or to and after PTCA. 
The pre~em study therefore invest~gated whether troponin T (cTnT) allows 
to predict this benefit, 
Methods and Resuffs: In 226 of 546 (41%) pts receiving aboximab and 
219 of 547 (40%) pts recewmg placebo cTnT L.0.t0 noJml) was found on 
study entq/. Event rates (death, AMI) dunng the 24 to 36 hours treatment 
phase before coronary interventions: 
cTnT nag CTnT pos p-value 
aboxrmaD 06% 0.9% ns 
Placebo O 9°¢' 4 1% p = 003 
p-v..~mue n:; p = 0 03 
Ounng the following PTCA abciximab reduced nsk in cTnT pos, as well 
as cTnT neg. pts (4.8% placebo vs. 19%. p = 0.04) 
Conctumons: cTnT identifies pts w~th unstable angina who benefit from 
abciximab through eliminating exCessive nsk prior to PTCA. Therefore. it 
may serve as a marker to initiate this treatment. All pts benefit equally from 
abeiximab during interventions, 
